造血干细胞移植相关血栓性微血管病的发病机制、诊断和治疗现状

国际输血及血液学杂志 Pub Date : 2019-11-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.06.001

X. Liu

{"title":"造血干细胞移植相关血栓性微血管病的发病机制、诊断和治疗现状","authors":"X. Liu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.06.001","DOIUrl":null,"url":null,"abstract":"Transplantation associated thrombotic microangiopathy (TA-TMA) is a significant complication after hematopoietic stem cell transplantation (HSCT), and may lead to a high risk of death. It is a multifactorial disorder focused on small vessel endothelial injury which can be trigged by varieties of mechanisms during HSCT. The complement system is found to play a role in the development of TA-TMA. Current laboratory diagnostic criteria are unsatisfactory and the latest diagnostic criterion includes activation of the complement system. But the pathological diagnosis remains to be the golden standard. Blocking the complement system with eculizumab may be one of the effective treatment for high-risk patients with TA-TMA. This article reviews the status on pathogenesis, diagnosis and treatment of TA-TMA. \n \n \nKey words: \nThrombotic microangiopathies; Hematopoietic stem cell transplantation; Endothelium, vascular; Complement system proteins; Transplantation associated thrombotic microangiopathy; Endothelial injury; Eculizumab","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"461-468"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Status on pathogenesis, diagnosis and treatment of hematopoietic stem cell transplantation associated thrombotic microangiopathy\",\"authors\":\"X. Liu\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.06.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Transplantation associated thrombotic microangiopathy (TA-TMA) is a significant complication after hematopoietic stem cell transplantation (HSCT), and may lead to a high risk of death. It is a multifactorial disorder focused on small vessel endothelial injury which can be trigged by varieties of mechanisms during HSCT. The complement system is found to play a role in the development of TA-TMA. Current laboratory diagnostic criteria are unsatisfactory and the latest diagnostic criterion includes activation of the complement system. But the pathological diagnosis remains to be the golden standard. Blocking the complement system with eculizumab may be one of the effective treatment for high-risk patients with TA-TMA. This article reviews the status on pathogenesis, diagnosis and treatment of TA-TMA. \\n \\n \\nKey words: \\nThrombotic microangiopathies; Hematopoietic stem cell transplantation; Endothelium, vascular; Complement system proteins; Transplantation associated thrombotic microangiopathy; Endothelial injury; Eculizumab\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"461-468\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.06.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

移植相关血栓性微血管病（TA-TMA）是造血干细胞移植（HSCT）后的一种重要并发症，可能导致高死亡风险。它是一种多因素的疾病，主要集中在小血管内皮损伤，在HSCT过程中可能由多种机制触发。补体系统被发现在TA-TMA的发展中发挥作用。目前的实验室诊断标准不令人满意，最新的诊断标准包括补体系统的激活。但病理诊断仍然是金标准。用埃库珠单抗阻断补体系统可能是治疗TA-TMA高危患者的有效方法之一。本文就TA-TMA的发病机制、诊断和治疗现状进行综述。关键词：血栓性微血管病；造血干细胞移植；内皮，血管；补体系统蛋白；移植相关血栓性微血管病；内皮损伤；Eculizumab

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Status on pathogenesis, diagnosis and treatment of hematopoietic stem cell transplantation associated thrombotic microangiopathy

Transplantation associated thrombotic microangiopathy (TA-TMA) is a significant complication after hematopoietic stem cell transplantation (HSCT), and may lead to a high risk of death. It is a multifactorial disorder focused on small vessel endothelial injury which can be trigged by varieties of mechanisms during HSCT. The complement system is found to play a role in the development of TA-TMA. Current laboratory diagnostic criteria are unsatisfactory and the latest diagnostic criterion includes activation of the complement system. But the pathological diagnosis remains to be the golden standard. Blocking the complement system with eculizumab may be one of the effective treatment for high-risk patients with TA-TMA. This article reviews the status on pathogenesis, diagnosis and treatment of TA-TMA. Key words: Thrombotic microangiopathies; Hematopoietic stem cell transplantation; Endothelium, vascular; Complement system proteins; Transplantation associated thrombotic microangiopathy; Endothelial injury; Eculizumab

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.